// App-Quantinova.ai

POS0925 (2021) : EFFICACY OF SECUKINUMAB IN TNFI-NAÏVE PATIENTS ACROSS THE AXIAL SPONDYLOARTHRITIS SPECTRUM OVER 52 WEEKS: A POST HOC ANALYSIS OF THE MEASURE AND PREVENT CLINICAL TRIALS

Researchers

Presenter

  • M. Magrey

Principal Investigators

  • J. A. Walsh

  • F. Huang

  • H. Kameda

  • J. Wang

  • P. Pertel

  • H. Marzo-Ortega

Medical Centers

  • Case Western Reserve University School of Medicine, Division of Rheumatology, Ohio, United States of America

  • Salt Lake City Veteran Affairs Medical Center; University of Utah Medical Center, Salt Lake City, Division of Rheumatology, Utah, United States of America

  • Chinese PLA General Hospital, Beijing, Department of Rheumatology and Immunology, Beijing, China

  • Toho University (Ohashi Medical Center), Department of Internal Medicine, Division of Rheumatology, Tokyo, Japan

  • Novartis Pharma AG, Rheumatology, Basel, Switzerland

  • Novartis Pharma AG, Immunology, Hepatology and Dermatology Development Unit, Basel, Switzerland

  • NIHR Leeds Biomedical Research Centre, Leeds Training Hospitals NHS Trust and LIRMM, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom

Locations

  • United States

  • China

  • Japan

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

  • Non-radiographic axial spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • AbbVie and UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved